Tekla Capital Management LLC Avadel Pharmaceuticals PLC Transaction History

Tekla Capital Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$6.61 - $10.07 $1.54 Million - $2.35 Million	-233,612 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$7.25 - $11.75 $2.41 Million - $3.91 Million	-332,454 Reduced 58.73%	233,612 $1.89 Million
Q1 2020 May 14, 2020	SELL	$4.06 - $10.64 $1.01 Million - $2.64 Million	-248,522 Reduced 30.51%	566,066 $4.5 Million
Q1 2018 May 14, 2018	BUY	$6.76 - $11.7 $1.29 Million - $2.23 Million	190,300 Added 30.48%	814,588 $5.94 Million
Q2 2017 Aug 14, 2017	BUY	N/A	624,288	624,288 $6.89 Million

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $661M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Tekla Capital Management LLC with notifications on news.